Mitsubishi UFJ Securities Holdings Co. Ltd. bought a new stake in Boston Scientific Co. (NYSE:BSX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,380 shares of the medical equipment provider’s stock, valued at approximately $91,000.

Other large investors have also recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at approximately $28,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Boston Scientific by 60.0% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 800 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 300 shares in the last quarter. Essex Savings Bank acquired a new position in shares of Boston Scientific in the 1st quarter valued at approximately $31,000. Hanson McClain Inc. raised its position in shares of Boston Scientific by 107.6% in the 1st quarter. Hanson McClain Inc. now owns 903 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 468 shares in the last quarter. Finally, Sontag Advisory LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at approximately $37,000. Institutional investors own 90.80% of the company’s stock.

NYSE BSX traded down $0.41 on Wednesday, hitting $40.76. The company’s stock had a trading volume of 195,327 shares, compared to its average volume of 7,879,935. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.12 and a current ratio of 1.39. Boston Scientific Co. has a 1-year low of $31.55 and a 1-year high of $41.99. The stock has a market cap of $57.95 billion, a P/E ratio of 27.70, a price-to-earnings-growth ratio of 2.45 and a beta of 0.75.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by ($0.01). Boston Scientific had a net margin of 18.08% and a return on equity of 24.65%. The business had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.54 billion. During the same quarter last year, the company posted $0.33 earnings per share. The company’s revenue was up 4.8% compared to the same quarter last year. Analysts predict that Boston Scientific Co. will post 1.55 earnings per share for the current fiscal year.

In other Boston Scientific news, CFO Daniel J. Brennan sold 46,360 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $40.02, for a total value of $1,855,327.20. Following the completion of the transaction, the chief financial officer now directly owns 214,960 shares in the company, valued at approximately $8,602,699.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Maulik Nanavaty sold 3,038 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.11, for a total transaction of $121,854.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 103,157 shares of company stock valued at $4,041,963. Corporate insiders own 0.66% of the company’s stock.

A number of equities analysts recently issued reports on BSX shares. Argus upped their price objective on shares of Boston Scientific from $43.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 13th. Evercore ISI upgraded shares of Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 price objective for the company in a research report on Monday, May 13th. Canaccord Genuity lowered their price objective on shares of Boston Scientific from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price objective on shares of Boston Scientific in a research report on Monday, May 13th. Finally, BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $41.87.

TRADEMARK VIOLATION NOTICE: “Mitsubishi UFJ Securities Holdings Co. Ltd. Buys New Stake in Boston Scientific Co. (NYSE:BSX)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2019/06/12/mitsubishi-ufj-securities-holdings-co-ltd-buys-new-stake-in-boston-scientific-co-nysebsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Read More: What is a Market Correction?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.